Sameer Rastogi, Additional Professor at All India Institute of Medical Sciences, shared a post on X:

“Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths.”

Title: Efficacy and Tolerability of a Low-Dose Continuous Regimen of Regorafenib in Refractory Synovial Sarcomas: A Single-Arm, Phase II Trial From India

Authors: Sanal Fernandes, Sameer Rastogi, Kanu Priya Bhatia, Shamim A. Shamim, Adarsh Barwad, Rambha Pandey, Shivanand Gammanagatti, Ekta Dhamija

Read Full Article.

Low-dose Regorafenib

More posts featuring Sameer Rastogi on OncoDaily.

Sameer Raastogi Shared Phase 2 Trial Results For Low-dose Regorafenib in Relapsed Synovial Sarcoma

“Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths.”